HER2 Low-Amplified Breast Cancer: The Efficacy of Anti-HER2 Therapy in Neoadjuvant Setting

被引：0
|
作者：
Lv, Hong [1 ]
Bai, Qianming [1 ]
Shui, Ruohong [1 ]
Xu, Xiaoli [1 ]
Yu, Bao-Hua [1 ]
Bi, Rui [2 ]
Cheng, Yufan [1 ]
Tu, Xiaoyu [1 ]
Zhou, Xiaoyan [2 ]
Yang, Wentao [1 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai, Peoples R China
来源：
LABORATORY INVESTIGATION | 2023年 / 103卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
187
引用
收藏
页码：S177 / S178
页数：2
相关论文
共 50 条
  • [1] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    [J]. LABORATORY INVESTIGATION, 2018, 98 : 91 - 91
  • [2] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    [J]. CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [3] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [4] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy.
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    [J]. MODERN PATHOLOGY, 2018, 31 : 91 - 91
  • [5] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [6] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Elisa Van Raemdonck
    G. Floris
    P. Berteloot
    A. Laenen
    I. Vergote
    H. Wildiers
    K. Punie
    P. Neven
    [J]. Breast Cancer Research and Treatment, 2021, 185 : 183 - 194
  • [7] HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
    Advani, Pooja P.
    Crozier, Jennifer A.
    Perez, Edith A.
    [J]. BIOMARKERS IN MEDICINE, 2015, 9 (01) : 35 - 49
  • [8] Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer
    Yu, Anthony F.
    Singh, Jasmeet C.
    Wang, Rui
    Liu, Jennifer E.
    Eaton, Anne
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    [J]. ONCOLOGIST, 2017, 22 (06): : 642 - 647
  • [9] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    [J]. MEDICINE, 2021, 100 (44)
  • [10] BREAST CANCER BIOMARKERS AND HER2 TESTING AFTER 10 YEARS OF ANTI-HER2 THERAPY
    Ross, Jeffrey S.
    [J]. DRUG NEWS & PERSPECTIVES, 2009, 22 (02) : 93 - 106
12345